{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T18:14:27Z","timestamp":1788718467387,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.esmoop.2024.103939","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T20:19:28Z","timestamp":1728677968000},"page":"103939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (\u226575 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-8151","authenticated-orcid":false,"given":"A.","family":"Mouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kisohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1281-2412","authenticated-orcid":false,"given":"T.","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9249-7904","authenticated-orcid":false,"given":"T.","family":"Makiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0394-7377","authenticated-orcid":false,"given":"A.","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4523-8517","authenticated-orcid":false,"given":"H.","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6468-9068","authenticated-orcid":false,"given":"K.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-1943","authenticated-orcid":false,"given":"M.","family":"Maemondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.103939_bib1","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103939_bib2","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103939_bib3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcome from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib4","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.2009.24.7577","article-title":"Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007","volume":"28","author":"Segawa","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung Cancer","volume":"34","author":"Senan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib7","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib8","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2014.60.0130","article-title":"Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSGLU05-04","volume":"33","author":"Ahn","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(12)70139-0","article-title":"Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomized, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)","volume":"13","author":"Atagi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cllc.2021.05.009","article-title":"Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable stage III non-small-cell lung cancer (PACIFIC)","volume":"22","author":"Socinski","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2024.103939_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1186\/s12885-020-07406-y","article-title":"A\u00a0phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 form 75 years: NEJ039A (trial in progress)","volume":"20","author":"Kaira","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2024.103939_bib13","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.7314\/APJCP.2014.15.6.2465","article-title":"Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system","volume":"15","author":"Arslan","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.esmoop.2024.103939_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: implications for research","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s002800050689","article-title":"Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer","volume":"40","author":"Kubota","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2024.103939_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100761","article-title":"Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer-a study in AIO oncologists","volume":"8","author":"B\u00fcttelmann","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.103939_bib17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.22.01118","article-title":"A\u00a0two-step frailty assessment strategy in older patients with solid tumors: a decision curve analysis","volume":"41","author":"Gonz\u00e1lez Serrano","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib18","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S1470-2045(12)70259-0","article-title":"Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review","volume":"13","author":"Hamaker","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2021.08.019","article-title":"Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005\/CRIMSON)","volume":"161","author":"Saito","year":"2021","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103939_bib20","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","article-title":"Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: a systematic review and meta-analysis","volume":"112","author":"Wang","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2024.103939_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cllc.2021.08.006","article-title":"Real-world incidence of pneumonitis in patients receiving durvalumab","volume":"23","author":"LeClair","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2024.103939_bib22","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1200\/JCO.2003.12.019","article-title":"The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly","volume":"21","author":"Schild","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib23","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/JTO.0b013e318213f86a","article-title":"Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007","volume":"6","author":"Takigawa","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100042","article-title":"A\u00a0prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study","volume":"6","author":"Gomes","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.103939_bib25","doi-asserted-by":"crossref","first-page":"8993","DOI":"10.1007\/s00432-023-04792-1","article-title":"Predictors of immune checkpoint inhibitor-related adverse events in older patients with lung cancer: a prospective real-world analysis","volume":"149","author":"Gao","year":"2023","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103939_bib26","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1200\/JCO.2013.49.6125","article-title":"End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society of Geriatric Oncology position article","volume":"31","author":"Wildiers","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924017095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924017095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T23:12:14Z","timestamp":1729811534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924017095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2059702924017095"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103939","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (\u226575 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103939"}}